Plasma Level of Oxidized Low- Density Lipoprotein in Macroalbuminuric
,
Abstract
Accumulating evidence suggest that in patients with diabetes mellitus, increased rate of lipoprotein oxidation and oxidative stress have important role in diabetic angiopathy, including nephropathy. To evaluate the association of oxidized low- density lipoprotein (ox-LDL) with the development of diabetic nephropathy, plasma level of ox-LDL were measured in 70 diabetic patients with macro and 63 patients with normoalbuminuria. The plasma oxidized- LDL level in patients with macroalbuminuria was higher than those in normoalbuminuric group, (85.72 ± 32.92 mu/L versus 75.07 ± 26.46 u/L, P= 0.041). hemoglobin A1C (HbA1C) levels were similar in diabetic patients with macro (9.0 ± 1.80%) and normoalbuminuria (8.52 ± 1.7%, P= 0.098). There was no significant correlation between the ox-LDL and HbA1C level. The significantly elevated plasma oxidized- LDL in patients with macroalbuminuria suggests that ox-LDL may play an important role in the progression of diabetic nephropathy.
Diamond JR. The role of reactive oxygen species in animal models of glomerular disease. Am J Kidney Dis 1992;19(3):292-300.
Wheeler DC, Chana RS, Topley N, Petersen MM, Davies M, Williams JD. Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int 1994;45(6):1628-36.
Ujihara N, Sakka Y, Takeda M, Hirayama M, Ishii A, Tomonaga O, et al. Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Diabetes Res Clin Pract 2002;58(2):109-14.
Abuja PM, Albertini R. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin Chim Acta 2001;306(1-2):1-17.
Coritsidis G, Rifici V, Gupta S, Rie J, Shan ZH, Neugarten J, et al. Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 1991;39(5):858-66.
Vessby J, Basu S, Mohsen R, Berne C, Vessby B. Oxidative stress and antioxidant status in type 1 diabetes mellitus. J Intern Med 2002;251(1):69-76.
Lee HS, Kim BC, Kim YS, Choi KH, Chung HK. Involvement of oxidation in LDL-induced collagen gene regulation in mesangial cells. Kidney Int 1996;50(5):1582-90.
Ding G, van Goor H, Ricardo SD, Orlowski JM, Diamond JR. Oxidized LDL stimulates the expression of TGF-beta and fibronectin in human glomerular epithelial cells. Kidney Int 1997;51(1):147-54.
Sato Y, Hotta N, Sakamoto N, Matsuoka S, Ohishi N, Yagi K. Lipid peroxide level in plasma of diabetic patients. Biochem Med 1979;21(1):104-7.
Girach A, Vignati L. Diabetic microvascular complications: can the presence of one predict the development of another? J Diabetes Complications 2006; 20(4):228-37.
Lee HS, Kim YS. Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int 1998;54(3):848-56.
Oranje WA, Wolffenbuttel BH. Lipid peroxidation and atherosclerosis in type II diabetes. J Lab Clin Med1999;134(1):19-32.
Schwenke DC, D'Agostino RB Jr, Goff DC Jr, Karter AJ, Rewers MJ, Wagenknecht LE; Insulin resistance atherosclerosis study. Differences in LDL oxidizability by glycemic status: the insulin resistance atherosclerosis study. Diabetes Care 2003;26(5):1449-55.
Oranje WA, Rondas-Colbers GJ, Swennen GN, Wolffenbuttel BH. Lipid peroxidation in type 2 diabetes: relationship with macrovascular disease? Neth J Med 1998; 53(2):61-8.
Gokulakrishnan K, Deepa R, Velmurugan K, Ravikumar R, Karkuzhali K, Mohan V. Oxidized low-density lipoprotein and intimal medial thickness in subjects with glucose intolerance: the Chennai Urban Rural Epidemiology Study-25. Metabolism 2007;56(2):245-50.
Kostić N, Caparević Z, Ilić S. Antioxidant status in type II diabetes mellitus patients with or without microvascular complications. Srp Arh Celok Lek 2007;135(3-4):143-6.
Tsuzura S, Ikeda Y, Suehiro T, Ota K, Osaki F, Arii K, et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 2004;53(3):297-302.
Wang H, Deng H, Liu W. The effects of paraoxonase-1and oxidized low density lipoprotein on nephropathy in type-2 diabetes mellitus. Zhonghua Nei Ke Za Zhi 2002;41(3):179-82.
Lamarche B, Lemieux I, Després JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999;25(3):199-211.
Atchley DH, Lopes-Virella MF, Zheng D, Kenny D, Virella G. Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia 2002;45(11):1562-71.
Grone HJ. Do oxidized lipoproteins contribute to glomerulosclerosis? Kidney Int 1998;54(3):995-6.
Magil AB, Frohlich JJ, Innis SM, Steinbrecher UP. Oxidized low-density lipoprotein in experimental focalglomerulosclerosis. Kidney Int 1993;43(6):1243-50.
Lee HS, Jeong JY, Kim BC, Kim YS, Zhang YZ, ChungHK. Dietary antioxidant inhibits lipoprotein oxidation andrenal injury in experimental focal segmental glomerulosclerosis. Kidney Int 1997;51(4):1151-9.
Coritsidis G, Rifici V, Gupta S, Rie J, Shan ZH, Neugarten J, et al. Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro.Kidney Int 1991;39(5):858-66.
Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 1993;22(1):72-82.
Moro E, Zambon C, Pianetti S, Cazzolato G, Pais M, Bittolo Bon G. Electronegative low density lipoprotein subform (LDL-) is increased in type 2 (non-insulindependent) microalbuminuric diabetic patients and is closely associated with LDL susceptibility to oxidation. Acta Diabetol 1998;35(3):161-4.
| Files | ||
| Issue | Vol 47, No 5 (2009) | |
| Section | Original Article(s) | |
| Keywords | ||
| Diabetic nephropathy oxidized low- density lipoprotein | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
